UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
May 2019
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On May 29, 2019, Akari Therapeutics, Plc (the “Company”) issued unaudited interim condensed consolidated financial statements as of March 31, 2019, prepared in accordance with generally accepted accounting principles in the United States, together with the Company’s Management Discussion and Analysis of Financial Condition and Results of Operations for the same period. Attached hereto and incorporated by reference herein are the following exhibits:
| 99.1 | Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2019 |
| 99.2 | Management Discussion and Analysis of Financial Condition and Results of Operations as of March 31, 2019 |
In addition, on May 29, 2019, the Company issued a press release announcing its first quarter 2019 financial results and recent clinical progress highlights. Further, on the same date, the Company updated its corporate presentation that it intends to use in conferences and meetings with investors. A copy of the press release and presentation are attached hereto as Exhibit 99.3 and 99.4, respectively, and incorporated herein by reference.
The information contained in Exhibits 99.1 and 99.2 and the statements under “First Quarter 2019 Financial Results”, the accompanying financial statements and “Cautionary Note Regarding Forward-Looking Statements” of Exhibit 99.3 are hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
| 99.1 | Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2019 |
| 99.2 | Management Discussion and Analysis of Financial Condition and Results of Operations as of March 31, 2019 |
| 99.3 | Press release dated May 29, 2019 |
| 99.4 | Corporate Presentation dated May 2019 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Akari Therapeutics, Plc | |
| | (Registrant) | |
| | | | |
| | By: | /s/ Clive Richardson | |
| | Name: | Clive Richardson Interim Chief Executive Officer and Chief Operating Officer | |
| | | |
Date: May 29, 2019
